Celsion Announces Enrollment Completion for Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
05. September 2018 08:00 ET
|
Celsion CORP
550 Patient Study Designed to Determine if ThermoDox® Can Significantly Prolong the Lives of Patients with Liver Cancer OPTIMA Study’s Hypothesis Independently Confirmed by the National Institutes...